Identification of a novel target site for ATP-independent ERK2 inhibitors.
Yoshida, M., Nagao, H., Sugiyama, H., Sawa, M., Kinoshita, T.(2022) Biochem Biophys Res Commun 593: 73-78
- PubMed: 35063772 
- DOI: https://doi.org/10.1016/j.bbrc.2022.01.035
- Primary Citation of Related Structures:  
7W5O - PubMed Abstract: 
Extracellular signal-regulated kinase 2 (ERK2) controls vital physiological processes involving proliferation and differentiation and is a drug target molecule for many diseases such as cancers. In silico screening focusing on an allosteric site that plays a crucial role in substrate anchoring conferred an ERK2 inhibitor (compound 1). However, a competitive binding assay indicated that compound 1 did not bind to the allosteric site. Here, the crystal structure of ERK2 in complex with compound 1 revealed a novel binding site. This finding demonstrates the feasibility of developing new types of ERK2 inhibitors.
Organizational Affiliation: 
Graduate School of Science, Osaka Prefecture University, Osaka, 599-8531, Japan.